Literature DB >> 3994210

Malignant melanoma of the choroid: treatment with episcleral 198Au plaque and xenon-arc photocoagulation.

R A Moura, A R McPherson, J Easley.   

Abstract

A method of treatment for posteriorly located malignant melanomas of the choroid is reviewed. Twenty-six patients have been treated either by radioactive gold (198Au) seed radiation plaque, alone or in combination with postradiation xenon-arc photocoagulation. Success, defined as the preservation of the globe with tumor ablated or regressed, was achieved in 92.3% of the treated eyes. These patients have been followed from 1 to 8.5 years, with an average follow-up of 44.84 months. Fifteen out of 26 patients (57.69%) had a final visual acuity of 20/50 or better. The main complications were radiation retinopathy (19.2%) and cystoid macular edema (19.2%). There were two enucleations, one after 29 months and one after 24 months following treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994210

Source DB:  PubMed          Journal:  Ann Ophthalmol        ISSN: 0003-4886


  4 in total

1.  A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma.

Authors:  E S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Indirect ophthalmoscope laser treatment as supplement to 125I plaque therapy for choroidal melanoma.

Authors:  J J Augsburger; D Mullen; M Kleineidam
Journal:  Trans Am Ophthalmol Soc       Date:  1992

3.  Histopathology studies in human malignant melanomas of the choroid after unsuccessful treatment with 106Ru/106Rh ophthalmic applicators.

Authors:  H Klaus; P K Lommatzsch; U Fuchs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

4.  Combined iodine-125 plaque irradiation and indirect ophthalmoscope laser therapy of choroidal malignant melanomas: comparison with iodine-125 and cobalt-60 plaque radiotherapy alone.

Authors:  J J Augsburger; M Kleineidam; D Mullen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-09       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.